Ziihera
zanidatamab-hrii · zanidatamab- Biliary Tract Cancer
- Gastroesophageal Adenocarcinoma
Zymeworks
Most recent annual filing: 2026-03-02
Pipeline (11 active programs)
pasritamig
JNJ-78278343ZW191
Protein Target: FRα, folate receptor alpha
ZW251
Protein Target: GPC3, glypican 3
ZW220
ZW209
Protein Target: DLL3, Delta-like ligand 3
ZW1528
Technology platforms
Azymetric
Multispecific antibody platform enabling bispecific and trispecific antibody development; produces both ADC backbones and multispecific therapeutics including TriTCE and ProTECT combinations; focus areas: oncology, inflammation, autoimmune disease
EFECT
Antibody effector function modulation platform consisting of Fc region modifications enabling selective enhancement or suppression of immune effector function; used in oncology, inflammation, and autoimmune therapeutics
ProTECT
Conditionally active antibody technology that masks an antibody arm outside the tumor to improve selectivity and minimize off-target toxicities; activated by tumor-specific proteases; focus: oncology tumor microenvironment
Biotech Distilled coverage (1)
Articles open on Substack. Some deep dives are subscriber-only.